The interaction of phenylephrine with MAO inhibitors causes a hypertensive effect, with tricyclic antidepressants (amitriptyline) - increases the risk of cardovascular side effects, with digoxin and cardiac glycosides - leads to arrhythmias and heart attack. Phenylephrine with other sympathomimetics increases the risk of adverse cardiovascular reactions, may reduce the effectiveness of β-blockers and other antihypertensive preparations (reserpine, methyldopa) with an increased risk of hypertension and adverse cardiovascular reactions. The simultaneous use of phenylephrine with ergot alakaloids (ergotamine and methysergide) may increase the risk of developing ergotism.
Oral ascorbic acid enhances the absorption of penicillin, iron, reduces the effectiveness of heparin and indirect anticoagulants, increases the risk of crystalluria in treatment with salicylates and the risk of glaucoma in treatment with glucocorticosteroids, large doses reduce the effectiveness of tricyclic antidepressants. Antidepressants, antiparkinsonian and antipsychotic preparations, phenothiazine derivatives increase the risk of urinary retention, dry mouth, and constipation. Ascorbic acid can be taken only 2 hours after the injection of deferoxamine, since their simultaneous intake increases the toxicity of iron, especially in the myocardium. Long-term use of large doses in the treatment of disulfiram inhibits the disulfiram-alcohol reaction.
Pheniramine enhances the anticholinergic effect of atropine, antispasmodics, tricyclic antidepressants, antiparkinsonian preparations. The simultaneous use of feniramine with hypnotics, barbiturates, sedatives, antipsychotics, tranquilizers, anesthetics, narcotic analgesics, alcohol can significantly increase its inhibitory effect.
The preparation should not be used simultaneously with alcohol.
It is necessary to consult a doctor about the possibility of using the preparation in patients with impaired renal and liver function. before using the preparation, it is necessary to consult a doctor if the patient is using warfarin or similar preparations that have an anticoagulant effect.
It should be borne in mind that in patients with alcoholic liver damage, the risk of the hepatotoxic effect of paracetamol increases; the preparation may affect the results of laboratory tests regarding the content of glucose and uric acid in the blood.
The danger of overdose arises in patients with non-cyrotic alcoholic liver disease.
Do not use simultaneously with other preparations prescribed for the symptomatic treatment of colds and rhinitis (vasoconstrictor, paracetamol-containing agents).
Patients who take analgesics every day for mild arthritis should consult a doctor.
Prescribe with caution for Raynaud's disease, arterial hypertension, heart disease, arrhythmias, bradycardia, thyroid, liver and kidney diseases, glaucoma, chronic lung diseases, prostatic hypertrophy, pheochromocytoma and elderly patients. The preparation contains phenylephrine, which can cause an attack of angina pectoris, and glucose, which is contraindicated in patients with intolerance and malabsorption of fructose, glucose-galactose or sucrose-isomaltose.
In patients with severe infections, such as sepsis, that are accompanied by a decrease in glutathione levels, the risk of metabolic acidosis increases with paracetamol. The symptoms of metabolic acidosis are deep, rapid or labored breathing, nausea, vomiting, and loss of appetite. You should immediately consult a doctor if these symptoms appear.
Do not exceed recommended doses.
If the signs of the disease do not begin to disappear within 3 days of treatment with the preparation, or, conversely, the state of health worsens, you should consult a doctor.
If the headache becomes persistent, you should see your doctor.
The preparation is contraindicated during pregnancy or lactation.
The ability to influence the reaction rate when driving or driving other mechanisms.
During treatment, it is not recommended to drive vehicles or other mechanisms, as the preparation may cause drowsiness.
Method of administration and dosage.
Dissolve the contents of the sachet in a glass of hot water (not boiling water) and drink. taking the preparation can be repeated every 3-4 hours, but not more than 3 sachets per day.
The duration of treatment is up to 5 days.
Children.
The preparation is contraindicated in children under 14 years of age.
Overdose.
Paracetamol. overdose, as a rule, is caused by paracetamol and is manifested by pallor of the skin, anorexia, nausea, vomiting, abdominal pain, hepatonecrosis, increased activity of hepatic transaminases and an increase in prothrombin index. in case of an overdose, there may be increased sweating, psychomotor agitation or depression of the central nervous system, drowsiness, impaired consciousness, heart rhythm disturbances, tachycardia, extrasystole, tremor, hyperreflexia, convulsions. when using large doses, disorientation, agitation, dizziness, sleep disturbance, heart rhythm and pancreatitis can be observed, nephrotoxicity is also possible (renal colic, interstitial nephritis, papillary necrosis). Acute renal failure with acute tubular necrosis may present with severe lumbar pain, hematuria, proteinuria, and develop even in the absence of severe liver damage.
In severe poisoning, impaired liver function can progress to encephalopathy with impaired consciousness, hemorrhage, hypoglycemia, cerebral edema, in some cases - with a fatal outcome. Liver damage is possible in adults who have taken more than 10 g, and in children who have taken more than 150 mg / kg of body weight. Taking 5 g or more of paracetamol can lead to liver damage in patients with risk factors (long-term treatment with carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St. , cystic fibrosis, HIV infection, hunger, cachexia).
The first clinical signs of hepatonecrosis may appear 12–48 hours after an overdose. Disorders of glucose metabolism and metabolic acidosis may occur. With prolonged use of high doses, aplastic anemia, pancytopenia, agranulocytosis, neutropenia, leukopenia, thrombocytopenia are possible.
In case of an overdose of phenylephrine, hyperhidrosis, psychomotor agitation or depression of the central nervous system, headache, dizziness, drowsiness, impaired consciousness, arrhythmias, tremors, hyperreflexia, convulsions, nausea, vomiting, irritability, anxiety, arterial hypertension occur.
With an overdose of pheniramine, atropine-like symptoms occur: mydriasis, photophobia, dry skin and mucous membranes, hyperthermia, intestinal atony. Inhibition of the central nervous system leads to disruption of the respiratory and cardiovascular systems (bradycardia, arterial hypotension, collapse).
In case of an overdose of ascorbic acid, nausea, vomiting, bloating and abdominal pain, itching, skin rashes, and increased excitability occur. Doses over 3000 mg can cause temporary osmotic diarrhea and gastrointestinal disorders, impaired metabolism of zinc, copper, myocardial dystrophy, glucosuria, crystalluria, nephrolithiasis.
Treatment. In case of an overdose, an ambulance is needed. The patient should be taken to hospital immediately, even if there are no early symptoms of overdose. Symptoms may be limited to nausea and vomiting, or may not reflect the severity of the overdose or the risk of organ damage. Treatment with activated charcoal should be considered if an overdose of paracetamol has been taken within 1 hour. The concentration of paracetamol in blood plasma should be measured 4 hours or later after ingestion (earlier concentrations are not reliable). Treatment with N-acetylcysteine can be applied within 24 hours after taking paracetamol, but the maximum protective effect occurs when it is used within 8 hours after taking it. The effectiveness of the antidote decreases sharply after this time. If necessary, the patient is injected intravenously with N-acetylcysteine according to the established list of doses. In the absence of vomiting, oral methionine can be used as an appropriate alternative in remote areas outside the hospital.
Side effects.
Stop using the preparation and immediately consult a doctor in case of adverse reactions.
Adverse reactions to paracetamol are very rare.
On the part of the skin: itching, dermatitis.
From the immune system: hypersensitivity reactions, including anaphylactic shock; itching; rashes on the skin and mucous membranes (usually generalized and erythematous, urticaria); angioedema; exudative erythema multiforme (including Stevens-Johnson syndrome); toxic epidermal necrolysis (Lyell's syndrome).
From the nervous system: headache, dizziness, tremors, psychomotor agitation and disorientation, anxiety, nervous excitement, fear, irritability, sleep disturbances, insomnia, drowsiness, confusion, hallucinations, depressions, paresthesias, tinnitus; in some cases - coma, convulsions, dyskinesia, behavior change.
From the respiratory system: bronchospasm in patients sensitive to acetylsalicylic acid and other nonsteroidal anti-inflammatory preparations.
From the side of the organs of vision: impaired vision and accommodation, mydriasis, increased intraocular pressure, dry eyes.
From the digestive tract: nausea, vomiting, heartburn, dry mouth, discomfort and pain in the epigastric region, constipation, diarrhea, flatulence, anorexia, aphthae, hypersalivation, hemorrhages.
On the part of the hepatobiliary system: impaired liver function, increased activity of hepatic enzymes, usually without the development of jaundice; hepatonecrosis (dose-dependent effect).
From the endocrine system: hypoglycemia up to hypoglycemic coma.
From the side of the blood system: anemia, including hemolytic anemia, sulfhemoglobinemia and methemoglobinemia (cyanosis, shortness of breath, pain in the heart); thrombocytopenia; agranulocytosis; bruising or bleeding.
From the urinary system: nephrotoxicity, interstitial nephritis, capillary necrosis, dysuria, urinary retention and difficulty urinating, renal colic, crystalluria, kidney stones.
From the side of the cardiovascular system: arterial hypertension, tachycardia, bradycardia, arrhythmia, shortness of breath, pain in the region of the heart.
Others: general weakness.
Storage conditions.
Store in its original packaging at a temperature not exceeding 25 ° C.
Keep out of the reach of children.